We did not observe an association between 9p21 deletions (CDKN2A, CDKN2B, MTAP) and survival in non-squamous NSCLC patients treated with chemotherapy-immunotherapy combination treatment. This evidence concerns the gene CDKN2B and non-small cell lung carcinoma.